Status:
COMPLETED
Prevalence of Severe Bleeding in COVID-19 Patients Treated With Higher Than Recommended Thromboprophylaxis Doses
Lead Sponsor:
Manuel Monreal
Conditions:
COVID-19
Eligibility:
All Genders
Brief Summary
The main objectives are: * To establish the prevalence of major bleeding in patients treated with higher than recommended thromboprophylaxis doses. * To identify variables associated to higher risk o...
Eligibility Criteria
Inclusion
- Patients infected with COVID-19 treated with higher than recommended thromboprophylaxis doses.
- Admission to hospital.
Exclusion
- Patients treated with ECMO (Extracorporeal membrane oxygenation).
Key Trial Info
Start Date :
April 13 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 13 2020
Estimated Enrollment :
2430 Patients enrolled
Trial Details
Trial ID
NCT04380779
Start Date
April 13 2020
End Date
October 13 2020
Last Update
December 14 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Manuel Monreal
Badalona, Barcelona, Spain, 08916